|
|
| | L-Alanine, L-tyrosyl-L-alanyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-glutaminyl-L-alanyl-L-arginyl-L-alanyl-L-lysyl-L-alanyl-L-leucyl-L-alanyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl- Basic information |
| | L-Alanine, L-tyrosyl-L-alanyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-glutaminyl-L-alanyl-L-arginyl-L-alanyl-L-lysyl-L-alanyl-L-leucyl-L-alanyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl- Chemical Properties |
| density | 1.46±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C, protect from light, stored under nitrogen | | form | Solid | | color | White to off-white | | Water Solubility | Water : 100 mg/mL (43.79 mM; Need ultrasonic) |
| | L-Alanine, L-tyrosyl-L-alanyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-glutaminyl-L-alanyl-L-arginyl-L-alanyl-L-lysyl-L-alanyl-L-leucyl-L-alanyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl- Usage And Synthesis |
| Uses | MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease[1]. | | in vivo | MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model[1]. | Animal Model: | 12-week-old C57Bl/6 wild type mice (intimal hyperplasia)[1] | | Dosage: | 100 μM | | Administration: | vein graft, 28 days | | Result: | Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts. |
| | References | [1] Akihito Muto, et al. Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul Pharmacol. Jan-Feb 2012;56(1-2):47-55. DOI:10.1016/j.vph.2011.07.008 |
| | L-Alanine, L-tyrosyl-L-alanyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-glutaminyl-L-alanyl-L-arginyl-L-alanyl-L-lysyl-L-alanyl-L-leucyl-L-alanyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl- Preparation Products And Raw materials |
|
|
Tag:L-Alanine, L-tyrosyl-L-alanyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-glutaminyl-L-alanyl-L-arginyl-L-alanyl-L-lysyl-L-alanyl-L-leucyl-L-alanyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl-(1039342-24-9)
Related Product Information
|
|
C-PEPTIDE (HUMAN)
2-Cyano-N-(2-hydroxy-1,1-dimethylethyl)-3-[3-(3,4,5-trimethoxyphenyl)-1H-indazol-5-yl]-2-propenamide
8H-[1,4]Diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one, 3-[[2-chloro-5-(ethoxymethyl)-4-pyrimidinyl]oxy]-9,10,11,12-tetrahydro-10-methyl-, (10R)-
Spiro[azetidine-3,10'-[10H]pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(6'H)-one, 2'-(2-fluorophenyl)-5',8',9',11'-tetrahydro-1-methyl-
[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-
4-[(3-Chloro-4-fluorophenyl)amino]-6-[(3-pyridinylmethyl)amino]-1,7-naphthyridine-3-carbonitrile
|